Usman Baber to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Usman Baber has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.253
-
Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J. 2007 Apr; 153(4):471-7.
Score: 0.271
-
Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 01; 123(11):1788-1795.
Score: 0.155
-
Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J. 2019 01; 207:10-18.
Score: 0.150
-
Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes. Sci Rep. 2017 08 01; 7(1):7001.
Score: 0.139
-
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. Circulation. 2017 May 30; 135(22):2091-2101.
Score: 0.135
-
Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment: The YELLOW II Study. J Am Coll Cardiol. 2017 Feb 14; 69(6):628-640.
Score: 0.132
-
A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. J Am Coll Cardiol. 2016 08 30; 68(9):881-91.
Score: 0.130
-
Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013 Jul 02; 62(1):21-9.
Score: 0.103
-
Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. Expert Rev Cardiovasc Ther. 2018 Nov; 16(11):825-835.
Score: 0.038